Navigation Links
ACE Inhibitor as Effective as More Expensive Blood Pressure Drug
Date:3/31/2008

Study focused on more than 17,000 people with coronary artery disease or diabetes

MONDAY, March 31 (HealthDay News) -- Treatment with an ACE inhibitor drug was as effective in reducing deaths, heart attacks and stroke in a high-risk group of patients as a newer and more expensive angiotensin-receptor blocker (ARB) drug, a large international study has found.

The study of more than 17,000 people with coronary artery disease or diabetes found no major differences between those treated with the widely used ACE inhibitor ramipril (Altace) and those given the ARB telmisartan (Micardis).

"This is the first study in such a population that shows ACE inhibitors are as effective as ARBs," said study leader Dr. Salim Yusuf, a professor of medicine at McMaster University, in Hamilton, Ontario, Canada.

The finding might reduce the use of ARBs for such high-risk people, he said. "Even before the trial, many physicians have used ACE inhibitors as a first choice," Yusuf said. "I believe it will have an impact on practice."

The findings were to be presented Monday at the American College of Cardiology annual meeting in Chicago, and will be published in the April 10 issue of the New England Journal of Medicine.

Both classes of drugs are prescribed to lower blood pressure. But they act in different ways to block the activity of angiotensin, a molecule that narrows blood vessels.

"The main value of ARBs as monotherapy in patients with cardiovascular disease is, in my opinion, as a substitute for an ACE inhibitor in a patient who cannot tolerate the ACE inhibitor because of cough," said Dr. John J.V. McMurray, a professor of medical cardiology at the University of Glasgow in Scotland, who wrote an editorial accompanying the journal report.

"ACE inhibitors have never been tested in an outcome study in this patient population, and an ACE inhibitor and ARB have never been compared in this patient population," McMurray noted.

During a median follow-up time of 56 months, the incidence of deaths and adverse events was almost identical in the two groups -- 16.5 percent for those taking ramipril and 16.7 percent in the telmisartan group. It was also about the same in a group prescribed both medications, 16.3 percent, but there was a higher incidence of side effects such as abnormally low blood pressure and kidney problems among those taking the combination drug therapy.

ARBs still have a place in treatment of high-risk people such as those in the study, Yusuf said. "About 20 to 30 percent of people who take ACE inhibitors have side effects that make them stop," he said. The most common side effect is cough.

"On the other hand, ARBs seem to be valuable when added to an ACE inhibitor in patients with heart failure," McMurray said. The new study group did not include people with heart failure.

Switching from an ARB to an ACE inhibitor can reduce the cost of medical care, Yusuf said. Pill for pill, the cost of an ARB is about 20 percent higher than for an ACE inhibitor in Canada, he said.

More information

Learn more about ACE inhibitors, ARBs and other drugs for high blood pressure from the American Heart Association.



SOURCES: Salim Yusuf, M.D., professor, medicine, McMaster University, Hamilton, Ontario; John J.V. McMurray, M.D., professor, medical cardiology, University of Glasgow, Scotland; March 31, 2008, presentation, American College of Cardiology annual meeting, Chicago; April 10, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
2. Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer
3. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
4. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
5. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
6. Silencing small but mighty cancer inhibitors
7. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
8. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
9. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
10. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
11. Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ACE Inhibitor as Effective as More Expensive Blood Pressure Drug
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician ... one of their physicians has been invited to be a featured speaker at the ... Review conference on April 30, 2016. , Dr. R. Scott McPherson, a physical ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... (CCA), is pleased to announce the launch of the GFCP Scoop ... and more. The purpose of the GFCP Scoop site is to ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Reltok ... devices and products for the head and neck/ear, nose and throat specialty, has added ... , The KOTLER NASAL AIRWAYâ„¢ is a newly patented safety device secured ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... YORK , April 28, 2016 ... online consumer insights on healthcare, announced today that it ... their report Cool Vendor in Life Sciences, 2016, ... April 15, 2016.  The report focuses on life-science- oriented ... gain insight from patients and doctors, confirm medication ingestion, ...
Breaking Medicine Technology: